Literature DB >> 17259498

How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes?

Richard A Chudleigh1, Gareth Dunseath, William Evans, John N Harvey, Philip Evans, Richard Ollerton, David R Owens.   

Abstract

OBJECTIVE: The Cockcroft-Gault (CG) and Modification of Diet in Renal Disease (MDRD) equations previously have been recommended to estimate glomerular filtration rate (GFR). We compared both estimates with true GFR, measured by the isotopic (51)Cr-EDTA method, in newly diagnosed, treatment-naïve subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 292 mainly normoalbuminuric (241 of 292) subjects were recruited. Subjects were classified as having mild renal impairment (group 1, GFR <90 ml/min per 1.73 m(2)) or normal renal function (group 2, GFR >/=90 ml/min per 1.73 m(2)). Estimated GFR (eGFR) was calculated by the CG and MDRD equations. Blood samples drawn at 44, 120, 180, and 240 min after administration of 1 MBq of (51)Cr-EDTA were used to measure isotopic GFR (iGFR).
RESULTS: For subjects in group 1, mean (+/-SD) iGFR was 83.8 +/- 4.3 ml/min per 1.73 m(2). eGFR was 78.0 +/- 16.5 or 73.7 +/- 12.0 ml/min per 1.73 m(2) using CG and MDRD equations, respectively. Ninety-five percent CIs for method bias were -11.1 to -0.6 using CG and -14.4 to -7.0 using MDRD. Ninety-five percent limits of agreement (mean bias +/- 2 SD) were -37.2 to 25.6 and -33.1 to 11.7, respectively. In group 2, iGFR was 119.4 +/- 20.3 ml/min per 1.73 m(2). eGFR was 104.4 +/- 26.3 or 92.3 +/- 18.7 ml/min per 1.73 m(2) using CG and MDRD equations, respectively. Ninety-five percent CIs for method bias were -17.4 to -12.5 using CG and -29.1 to -25.1 using MDRD. Ninety-five percent limits of agreement were -54.4 to 24.4 and -59.5 to 5.3, respectively.
CONCLUSIONS: In newly diagnosed type 2 diabetic patients, particularly those with a GFR >/=90 ml/min per 1.73 m(2), both CG and MDRD equations significantly underestimate iGFR. This highlights a limitation in the use of eGFR in the majority of diabetic subjects outside the setting of chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17259498     DOI: 10.2337/dc06-1688

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  14 in total

1.  Association of the Q121 variant of ENPP1 gene with decreased kidney function among patients with type 2 diabetes.

Authors:  Salvatore De Cosmo; Antonio Minenna; Yuan-Yuan Zhang; Ryan Thompson; Robert Thompson; Giuseppe Miscio; Monica Vedovato; Anna Rauseo; Alois Saller; Sandra Mastroianno; Fabio Pellegrini; Roberto Trevisan; Paola Fioretto; Alessandro Doria; Vincenzo Trischitta
Journal:  Am J Kidney Dis       Date:  2008-10-31       Impact factor: 8.860

2.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

Authors:  T M E Davis; R Ting; J D Best; M W Donoghoe; P L Drury; D R Sullivan; A J Jenkins; R L O'Connell; M J Whiting; P P Glasziou; R J Simes; Y A Kesäniemi; V J Gebski; R S Scott; A C Keech
Journal:  Diabetologia       Date:  2010-11-04       Impact factor: 10.122

3.  Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease.

Authors:  Vincent Rigalleau; Magalie Garcia; Catherine Lasseur; François Laurent; Michel Montaudon; Christelle Raffaitin; Nicole Barthe; Marie-Christine Beauvieux; Benoit Vendrely; Philippe Chauveau; Christian Combe; Henri Gin
Journal:  BMC Nephrol       Date:  2010-03-03       Impact factor: 2.388

Review 4.  Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment.

Authors:  Andrew Kowalski; Armand Krikorian; Edgar V Lerma
Journal:  Ochsner J       Date:  2014

Review 5.  Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Rev Diabet Stud       Date:  2015-08-10

6.  The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.

Authors:  Bunyong Phakdeekitcharoen; Watcharapong Treesinchai; Pornphan Wibulpolprasert; Sarinya Boongird; Pinkael Klytrayong
Journal:  BMC Nephrol       Date:  2021-05-15       Impact factor: 2.388

7.  Glomerular hyperfiltration and renal disease progression in type 2 diabetes.

Authors:  Piero Ruggenenti; Esteban L Porrini; Flavio Gaspari; Nicola Motterlini; Antonio Cannata; Fabiola Carrara; Claudia Cella; Silvia Ferrari; Nadia Stucchi; Aneliya Parvanova; Ilian Iliev; Alessandro Roberto Dodesini; Roberto Trevisan; Antonio Bossi; Jelka Zaletel; Giuseppe Remuzzi
Journal:  Diabetes Care       Date:  2012-07-06       Impact factor: 19.112

8.  Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study.

Authors:  Piero Ruggenenti; Flavio Gaspari; Antonio Cannata; Fabiola Carrara; Claudia Cella; Silvia Ferrari; Nadia Stucchi; Silvia Prandini; Bogdan Ene-Iordache; Olimpia Diadei; Norberto Perico; Patrizia Ondei; Antonio Pisani; Erasmo Buongiorno; Piergiorgio Messa; Mauro Dugo; Giuseppe Remuzzi
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

9.  Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

Authors:  Ru-Dee Ting; Anthony C Keech; Paul L Drury; Mark W Donoghoe; John Hedley; Alicia J Jenkins; Timothy M E Davis; Seppo Lehto; David Celermajer; R John Simes; Kushwin Rajamani; Kim Stanton
Journal:  Diabetes Care       Date:  2011-12-30       Impact factor: 19.112

10.  Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes.

Authors:  Mee Kyoung Kim; Seung-Hyun Ko; Ki-Hyun Baek; Yu-Bae Ahn; Kun-Ho Yoon; Moo-Il Kang; Kwang-Woo Lee; Ki-Ho Song
Journal:  Korean J Intern Med       Date:  2009-08-26       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.